The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells
-
By
-
Xiaole Song
-
Shitong Lin
-
Qianwen Liu
-
Xuerou Chen
-
Yajuan Ma
-
Xiaoran Zhang
-
Fang Ren
-
June 17, 2026
-
Clinical Scorecard: The Impact of Aberrant Lactate Dehydrogenase A on Immune Cell Anti-Tumor Responses
At a Glance
| Category | Detail |
|---|
| Condition | Malignant tumors with aberrant LDHA expression |
| Key Mechanisms | LDHA-mediated glycolysis, Warburg effect, lactate accumulation, immune cell metabolic reprogramming |
| Target Population | Patients with various malignancies exhibiting LDHA overexpression |
| Care Setting | Oncology and immunotherapy |
Key Highlights
- LDHA is overexpressed in diverse human malignancies.
- LDHA modulates immune cell differentiation and function.
- Targeting LDHA may enhance anti-tumor immune responses.
- LDHA inhibitors could be combined with immunotherapies.
- Differential LDHA expression affects immune cell polarization.
Guideline-Based Recommendations
Diagnosis
- Assess LDHA expression in tumor tissues.
Management
- Consider LDHA as a therapeutic target in tumor immunotherapy.
Monitoring & Follow-up
- Monitor immune cell metabolic profiles in response to LDHA modulation.
Risks
- Potential for altered immune responses due to LDHA inhibition.
Patient & Prescribing Data
Patients with tumors exhibiting high LDHA levels.
Combining LDHA inhibitors with CAR-T therapy and immune checkpoint blockade may improve outcomes.
Clinical Best Practices
- Evaluate the metabolic status of tumor-infiltrating immune cells.
- Utilize LDHA expression profiles to inform treatment strategies.
- Integrate LDHA-targeted therapies with existing immunotherapies.
Related Resources & Content
